Fulgent Genetics (FLGT) Research & Development (2015 - 2026)

Fulgent Genetics has reported Research & Development for 12 years, with the latest figure at $15.2 million in Q2 2026.

• Quarterly Research & Development rose 12.97% year-over-year to $15.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $57.4 million (up 15.4% YoY) and the FY2025 annual result came in at $53.9 million, up 10.42% from the prior year.
• Research & Development grew to $15.2 million in Q2 2026 per FLGT's latest filing, from $14.2 million in the prior quarter.
• Over five years, Research & Development peaked at $15.2 million in Q2 2026 and troughed at $7.9 million in Q1 2022.
• A 5-year average of $11.8 million and a median of $11.6 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 104.56% in 2022, then decreased 1.32% in 2023.
• Over 5 years, Research & Development stood at $10.3 million in 2022, then grew by 2.41% to $10.5 million in 2023, then climbed by 15.36% to $12.1 million in 2024, then advanced by 16.98% to $14.2 million in 2025, then increased by 7.47% to $15.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.2 million, $14.2 million, and $14.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.